Public Employees Retirement System of Ohio Has $4.96 Million Position in Haemonetics Co. (HAE)

Public Employees Retirement System of Ohio grew its position in shares of Haemonetics Co. (NYSE:HAE) by 9.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,563 shares of the medical instruments supplier’s stock after buying an additional 4,334 shares during the quarter. Public Employees Retirement System of Ohio owned 0.10% of Haemonetics worth $4,959,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Financial Gravity Companies Inc. bought a new stake in shares of Haemonetics during the 4th quarter valued at $41,000. We Are One Seven LLC bought a new stake in Haemonetics in the 4th quarter valued at $51,000. Hanseatic Management Services Inc. increased its holdings in Haemonetics by 8,500.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 1,462 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 1,445 shares during the last quarter. Ffcm LLC increased its holdings in Haemonetics by 134.4% in the 4th quarter. Ffcm LLC now owns 1,744 shares of the medical instruments supplier’s stock valued at $174,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Advisor Group Inc. increased its holdings in Haemonetics by 614.5% in the 4th quarter. Advisor Group Inc. now owns 2,022 shares of the medical instruments supplier’s stock valued at $203,000 after acquiring an additional 1,739 shares during the last quarter. Hedge funds and other institutional investors own 99.60% of the company’s stock.

In other news, Director Ronald G. Gelbman sold 8,196 shares of the business’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $86.52, for a total value of $709,117.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michelle L. Basil sold 391 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $83.57, for a total transaction of $32,675.87. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,909 shares of company stock valued at $1,036,501. Company insiders own 1.04% of the company’s stock.

HAE stock opened at $86.48 on Friday. Haemonetics Co. has a 12 month low of $76.13 and a 12 month high of $117.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.44 and a quick ratio of 1.64. The stock has a market cap of $4.41 billion, a P/E ratio of 46.25, a PEG ratio of 2.23 and a beta of 0.88.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. The firm had revenue of $247.36 million during the quarter, compared to analysts’ expectations of $250.12 million. During the same period in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. As a group, research analysts expect that Haemonetics Co. will post 2.33 earnings per share for the current year.

HAE has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “sell” rating in a report on Tuesday, January 8th. ValuEngine cut shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 5th. Finally, Barrington Research lifted their price objective on shares of Haemonetics to $112.00 and gave the stock a “positive” rating in a research note on Wednesday, February 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $119.75.

COPYRIGHT VIOLATION WARNING: “Public Employees Retirement System of Ohio Has $4.96 Million Position in Haemonetics Co. (HAE)” was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/27/public-employees-retirement-system-of-ohio-has-4-96-million-position-in-haemonetics-co-hae.html.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: How to interpret the current ratio

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.